Table 2.
Clinical and histological features of ATM-associated invasive breast carcinomas compared with those of sporadic cases
| Clinicopathological variable | PICBIM series (N = 516) | ATM series (all tumours, TV + MS) (N = 36) | P value a | ATM series (1st primary tumours only) (N = 32) | P value a | ATM series (excluding MS in HBOC families) (N = 31) | P value a |
|---|---|---|---|---|---|---|---|
| Histological subtype | |||||||
| Ductal carcinoma | 434 | 30 | Reference | 27 | Reference | 25 | Reference |
| Lobular carcinoma | 54 | 2 | 0.55 | 2 | 0.69 | 2 | 0.78 |
| Others | 28 | 3 | 0.43 | 2 | 0.78 | 3 | 0.25 |
| Unknown | 0 | 1 | – | 1 | – | 1 | – |
| Histological grade | |||||||
| I | 88 | 4 | Reference | 3 | Reference | 4 | Reference |
| II | 191 | 16 | 0.34 | 15 | 0.24 | 13 | 0.58 |
| III | 236 | 15 | 0.64 | 13 | 0.55 | 14 | 0.75 |
| Unknown | 1 | 1 | – | 1 | – | – | – |
| Architecture | |||||||
| 1–2 | 126 | 0 | Reference | 7 | Reference | 6 | Reference |
| 3 | 390 | 30 | 0.97 | 21 | 0.86 | 20 | 0.96 |
| Unknown | 0 | 6 | – | 4 | – | 5 | – |
| Mitosis | |||||||
| 0–1 | 221 | 15 | Reference | 14 | Reference | 12 | Reference |
| 2 | 103 | 9 | 0.58 | 8 | 0.70 | 9 | 0.31 |
| 3 | 191 | 6 | 0.10 | 6 | 0.13 | 5 | 0.15 |
| Unknown | 1 | 6 | – | 4 | – | 5 | – |
| Nuclear grade | |||||||
| 1 | 30 | 2 | Reference | 2 | Reference | 2 | Reference |
| 2 | 225 | 7 | 0.25 | 7 | 0.22 | 5 | 0.12 |
| 3 | 261 | 21 | 0.96 | 19 | 0.89 | 19 | 0.9 |
| Unknown | 0 | 6 | – | 4 | – | 5 | – |
| Tumour size (cm) | |||||||
| pT1 (< 2) | 329 | 23 | Reference | 20 | Reference | 19 | Reference |
| pT2 (2–5) | 166 | 8 | 0.37 | 7 | 0.41 | 7 | 0.48 |
| pT3 (> 5) | 14 | 2 | 0.37 | 2 | 0.30 | 2 | 0.26 |
| pT4 | 7 | 0 | – | 0 | – | 0 | – |
| Unknown | 0 | 3 | – | 3 | – | 3 | – |
| Pushing margins | |||||||
| Absent | 461 | 19 | Reference | 17 | Reference | 15 | Reference |
| Present | 49 | 2 | 0.98 | 2 | 0.93 | 2 | 0.78 |
| Unknown | 6 | 15 | – | 13 | – | 14 | – |
| Emboli | |||||||
| Absent | 315 | 13 | Reference | 11 | Reference | 13 | Reference |
| Present | 199 | 14 | 0.08 | 14 | 0.04 | 11 | 0.32 |
| Unknown | 2 | 9 | – | 7 | – | 7 | – |
| N stage | |||||||
| pN0 | 286 | 18 | Reference | 15 | Reference | 15 | Reference |
| pN1 | 151 | 10 | 0.80 | 9 | 0.66 | 9 | 0.55 |
| pN2 | 59 | 1 | 0.23 | 1 | 0.32 | 1 | 0.35 |
| pN3 | 16 | 1 | 0.96 | 1 | 0.81 | 1 | 0.76 |
| pNx | 5 | 6 | – | 6 | – | 5 | – |
| Oestrogen receptor | |||||||
| Positive | 307 | 34 | Reference | 31 | Reference | 29 | Reference |
| Negative | 209 | 1 | 0.003 | 1 | 0.004 | 1 | 0.005 |
| Unknown | 0 | 1 | – | – | – | 1 | – |
| Progesterone receptor | |||||||
| Positive | 278 | 26 | Reference | 23 | Reference | 23 | Reference |
| Negative | 236 | 8 | 0.03 | 8 | 0.07 | 6 | 0.02 |
| Unknown | 2 | 2 | – | 1 | – | 2 | – |
| HER2 | |||||||
| Negative | 433 | 25 | Reference | 23 | Reference | 21 | Reference |
| Positive | 83 | 6 | 0.77 | 5 | 0.97 | 6 | 0.53 |
| Unknown | 0 | 5 | – | 4 | – | 4 | – |
| Ki-67 | |||||||
| < 20% | 173 | 11 | Reference | 10 | Reference | 8 | Reference |
| ≥ 20% | 336 | 18 | 0.55 | 17 | 0.59 | 17 | 0.97 |
| Unknown | 7 | 7 | – | 5 | – | 6 | – |
| Molecular subtype | |||||||
| TNBC | 142 | 1 | Reference | 1 | Reference | 1 | Reference |
| HER2 | 66 | 0 | N/A | 0 | N/A | 0 | N/A |
| Luminal A | 180 | 10 | 0.06 | 9 | 0.08 | 7 | 0.13 |
| Luminal B | 111 | 13 | 0.009 | 12 | 0.010 | 12 | 0.010 |
| Luminal B/HER2 | 17 | 4 | 0.005 | 4 | 0.005 | 4 | 0.005 |
| Unknown | 0 | 8 | – | 6 | – | 7 | – |
Abbreviations: ATM, Ataxia-telangiectasia mutated, HBOC Hereditary breast and ovarian cancer, HER2 Human epidermal growth factor receptor 2, MS Missense substitution, PICBIM Programme incitatif et collaboratif - Cancer du sein: invasion et motilité series, TV Truncating variant, TNBC Triple-negative breast cancer
a P value adjusted for sex and for age at diagnosis